BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37610648)

  • 1. PDGFRA, KIT, and KDR Gene Amplification in Glioblastoma: Heterogeneity and Clinical Significance.
    Carlotto BS; Trevisan P; Provenzi VO; Soares FP; Rosa RFM; Varella-Garcia M; Zen PRG
    Neuromolecular Med; 2023 Sep; 25(3):441-450. PubMed ID: 37610648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.
    Burford A; Little SE; Jury A; Popov S; Laxton R; Doey L; Al-Sarraj S; Jürgensmeier JM; Jones C
    PLoS One; 2013; 8(8):e71777. PubMed ID: 23990986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.
    Disel U; Madison R; Abhishek K; Chung JH; Trabucco SE; Matos AO; Frampton GM; Albacker LA; Reddy V; Karadurmus N; Benson A; Webster J; Paydas S; Cabanillas R; Nangia C; Ozturk MA; Millis SZ; Pal SK; Wilky B; Sokol ES; Gay LM; Soman S; Ganesan S; Janeway K; Stephens PJ; Zhu VW; Ou SI; Lovly CM; Gounder M; Schrock AB; Ross JS; Miller VA; Klempner SJ; Ali SM
    Oncologist; 2020 Jan; 25(1):e39-e47. PubMed ID: 31604903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study.
    Nobusawa S; Stawski R; Kim YH; Nakazato Y; Ohgaki H
    Neuropathology; 2011 Dec; 31(6):583-8. PubMed ID: 21382095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.
    Puputti M; Tynninen O; Sihto H; Blom T; Mäenpää H; Isola J; Paetau A; Joensuu H; Nupponen NN
    Mol Cancer Res; 2006 Dec; 4(12):927-34. PubMed ID: 17189383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.
    Szerlip NJ; Pedraza A; Chakravarty D; Azim M; McGuire J; Fang Y; Ozawa T; Holland EC; Huse JT; Jhanwar S; Leversha MA; Mikkelsen T; Brennan CW
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3041-6. PubMed ID: 22323597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
    Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
    J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment.
    Zietsch J; Ziegenhagen N; Heppner FL; Reuss D; von Deimling A; Holtkamp N
    PLoS One; 2010 Jul; 5(7):e11858. PubMed ID: 20686603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone--an array comparative genomic hybridization study.
    Niini T; López-Guerrero JA; Ninomiya S; Guled M; Hattinger CM; Michelacci F; Böhling T; Llombart-Bosch A; Picci P; Serra M; Knuutila S
    Genes Chromosomes Cancer; 2010 Feb; 49(2):132-43. PubMed ID: 19862822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme.
    Holtkamp N; Ziegenhagen N; Malzer E; Hartmann C; Giese A; von Deimling A
    Neuro Oncol; 2007 Jul; 9(3):291-7. PubMed ID: 17504929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors.
    Blom T; Roselli A; Häyry V; Tynninen O; Wartiovaara K; Korja M; Nordfors K; Haapasalo H; Nupponen NN
    J Neurooncol; 2010 Apr; 97(2):217-24. PubMed ID: 19779861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma.
    Phillips JJ; Aranda D; Ellison DW; Judkins AR; Croul SE; Brat DJ; Ligon KL; Horbinski C; Venneti S; Zadeh G; Santi M; Zhou S; Appin CL; Sioletic S; Sullivan LM; Martinez-Lage M; Robinson AE; Yong WH; Cloughesy T; Lai A; Phillips HS; Marshall R; Mueller S; Haas-Kogan DA; Molinaro AM; Perry A
    Brain Pathol; 2013 Sep; 23(5):565-73. PubMed ID: 23438035
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Hou H; Jia D; Yan W; Zhang X; Wang C; Li Y; Chen H; Huang W; Li Z; Zhang X
    Transl Cancer Res; 2020 Aug; 9(8):4703-4714. PubMed ID: 35117834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.
    Ozawa T; Brennan CW; Wang L; Squatrito M; Sasayama T; Nakada M; Huse JT; Pedraza A; Utsuki S; Yasui Y; Tandon A; Fomchenko EI; Oka H; Levine RL; Fujii K; Ladanyi M; Holland EC
    Genes Dev; 2010 Oct; 24(19):2205-18. PubMed ID: 20889717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A YAC contig spanning a cluster of human type III receptor protein tyrosine kinase genes (PDGFRA-KIT-KDR) in chromosome segment 4q12.
    Spritz RA; Strunk KM; Lee ST; Lu-Kuo JM; Ward DC; Le Paslier D; Altherr MR; Dorman TE; Moir DT
    Genomics; 1994 Jul; 22(2):431-6. PubMed ID: 7528718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines.
    Chakravarty D; Pedraza AM; Cotari J; Liu AH; Punko D; Kokroo A; Huse JT; Altan-Bonnet G; Brennan CW
    Sci Rep; 2017 Aug; 7(1):9043. PubMed ID: 28831081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-amplified with PDGFRA, IGFBP7 is a prognostic biomarker correlated with the immune infiltrations of glioma.
    Wang H; Wang X; Xu L; Zhang J
    Cancer Med; 2023 Feb; 12(4):4951-4967. PubMed ID: 36043552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma.
    Gai QJ; Fu Z; He J; Mao M; Yao XX; Qin Y; Lan X; Zhang L; Miao JY; Wang YX; Zhu J; Yang FC; Lu HM; Yan ZX; Chen FL; Shi Y; Ping YF; Cui YH; Zhang X; Liu X; Yao XH; Lv SQ; Bian XW; Wang Y
    Signal Transduct Target Ther; 2022 Feb; 7(1):33. PubMed ID: 35105853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
    McDermott U; Ames RY; Iafrate AJ; Maheswaran S; Stubbs H; Greninger P; McCutcheon K; Milano R; Tam A; Lee DY; Lucien L; Brannigan BW; Ulkus LE; Ma XJ; Erlander MG; Haber DA; Sharma SV; Settleman J
    Cancer Res; 2009 May; 69(9):3937-46. PubMed ID: 19366796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplification of chromosomal segment 4q12 in non-small cell lung cancer.
    Ramos AH; Dutt A; Mermel C; Perner S; Cho J; Lafargue CJ; Johnson LA; Stiedl AC; Tanaka KE; Bass AJ; Barretina J; Weir BA; Beroukhim R; Thomas RK; Minna JD; Chirieac LR; Lindeman NI; Giordano T; Beer DG; Wagner P; Wistuba II; Rubin MA; Meyerson M
    Cancer Biol Ther; 2009 Nov; 8(21):2042-50. PubMed ID: 19755855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.